SCM
ALXN

Soleus Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Soleus Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,318
Closed -$3.87M – 90
2021
Q1 		$3.87M Buy
25,318
+6,380
+34% +$987K 0.7% 26
2020
Q4 		$2.96M Sell
18,938
-11,139
-37% -$1.43M 0.39% 28
2020
Q3 		$3.44M Sell
30,077
-20,712
-41% -$2.23M 1.82% 22
2020
Q2 		$5.7M Buy
50,789
+2,989
+6% +$317K 3.25% 9
2020
Q1 		$4.29M Buy
47,800
+16,500
+53% +$1.62M 4.99% 6
2019
Q4 		$3.38M Buy
+31,300
New +$3.35M 3.26% 9

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Soleus Capital Management's ALXN Position: Q2 2021 in Review

Soleus Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 25,318 shares — an estimated $3.87M sold.

Soleus Capital Management first reported a position in ALXN in Q4 2019 and held it in 6 quarters. The position peaked at $5.7M in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Soleus Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Soleus Capital Management sold 25,318 Alexion Pharmaceuticals shares in Q2 2021, an estimated $3.87M.
  • Soleus Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Soleus Capital Management's Alexion Pharmaceuticals position peaked at $5.7M in Q2 2020.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.